提醒

提醒專業圖表

Puma Biotechnology Inc. (PBYI)

NasdaqGS: PBYI · 即時價格 · USD

8.71

-0.19 (-2.13%)

收盤時： Aug 13, 2026, 3:59 PM

8.71

+0.00%

盤後: 7:34 PM

-2.13% (1D)

買價	6.43
市值	449.61M
營收 (ttm)	231.24M
淨利（ttm）	26.72M
貝塔	1.22
EPS (ttm)	0.51
本益比（ttm）	17.42
正向 PE	24.89
P/B (ttm)	3.21
P/S (ttm)	1.94
Earnings Date	Nov 5, 2026

賣價	11.17
成交量	253,875
20 日平均成交量	310,014
打開	8.93
上一頁關閉	8.90
日間範圍	8.65 - 8.96
52 週範圍	4.30 - 9.40
分析師	Hold
目標價	6 (-31.11%)
股利	n/a
Ex-股利日期	n/a

關於PBYI

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib...

[閱讀更多]

工業 Biotechnology

部門 Healthcare

IPO 日期 Apr 24, 2012

員工 179

證券交易所 NasdaqGS

股票代號 PBYI

網站 https://www.pumabiotechnology.com

完整的公司簡介

財務表現

Puma Biotechnology 在 2025 年的營收為 228.37M，較前一年的 230.47M 減少 -0.91%。淨利為 31.11M，較前期增加 2.75%。

財務報表

分析師預測

根據1 分析師評等，PBYI股票的平均評等為「Hold」。 12個月股價預測為6，與最新價格相比為下跌風險的31.11%。

股票預測

獲利驚喜

Puma Biotechnology 已於 Aug 6, 2026 公布季度財報：

營收的 $56.5M 錯過估計 $0, 與 7.75% YoY 成長.

EPS 的 0.2 超出估計 0.13, 與 33.33% YoY 成長.

下次財報發布

Puma Biotechnology Inc. 定於發布財報 Nov 5, 2026, 在市場交易時間內。
分析師預估營收 ... 升級

新聞動態

1 日前 · Zacks

Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

6 天前 · Zacks

PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised

Puma Biotechnology tops Q2 earnings and revenue estimates, raises its 2026 guidance, and outlines upcoming alisertib study milestones as Nerlynx sales climb.

6 天前 · Moby

Puma Biotechnology, Inc. Q2 2026 Earnings Call Summary

Moby summary of Puma Biotechnology, Inc.'s Q2 2026 earnings call

6 天前 · MarketBeat

Puma Biotechnology Q2 Earnings Call Highlights

Puma Biotechnology (NASDAQ:PBYI) reported second-quarter 2026 total revenue of $56.5 million, including $53.6 million in net product revenue from NERLYNX and $2.9 million in royalty revenue. The compa...

6 天前 · GuruFocus.com

Puma Biotechnology Inc (PBYI) (Q2 2026) Earnings Call Highlights: Debt-Free Status and Raised ...

Puma Biotechnology Inc (PBYI) posts $8.2 million GAAP net income, raises full-year revenue and profit outlook, and advances its alisertib clinical program.

第 1 頁，共 2 頁

Puma Biotechnology Inc. (PBYI)